Serratiopeptidase

A systematic review identified 17 published clinical studies evaluating serrapeptase for a broad range of indications. Bhagat 2013 Most of these studies had poor methodology according to grading by the Scottish Intercollegiate Guidelines Network checklist. Limitations included small sample size, poorly defined enrollment criteria and outcomes, unclear statistical methods, short duration, and failure of some studies to report the dose and duration of therapy. Two low-quality studies evaluated serrapeptase as an adjunct to increase the penetration of antimicrobial drugs into sites of infection. Other conditions evaluated in the low-quality studies included postoperative or traumatic swelling, carpal tunnel syndrome, secretory otitis media, and chronic airway disease, but the resulting evidence was insufficient to evaluate the efficacy of serrapeptase for these indications. Among the 17 clinical studies identified, 5 were randomized controlled trials published in English and with a low risk of bias and are summarized in the following sections. Al-Khateeb 2008 , Chopra 2009 , Kee 1989 , Mazzone 1990 , Tachibana 1984

A systematic review identified 17 published clinical studies evaluating serrapeptase for a broad range of indications. Bhagat 2013 Most of these studies had poor methodology according to grading by the Scottish Intercollegiate Guidelines Network checklist. Limitations included small sample size, poorly defined enrollment criteria and outcomes, unclear statistical methods, short duration, and failure of some studies to report the dose and duration of therapy. Two low-quality studies evaluated serrapeptase as an adjunct to increase the penetration of antimicrobial drugs into sites of infection. Other conditions evaluated in the low-quality studies included postoperative or traumatic swelling, carpal tunnel syndrome, secretory otitis media, and chronic airway disease, but the resulting evidence was insufficient to evaluate the efficacy of serrapeptase for these indications. Among the 17 clinical studies identified, 5 were randomized controlled trials published in English and with a low risk of bias and are summarized in the following sections. Al-Khateeb 2008 , Chopra 2009 , Kee 1989 , Mazzone 1990 , Tachibana 1984

Serratiopeptidase is contraindicated in conditions like Hypersensitivity, Coagulation disorder.

The symptomatic adverse reactions produced by Serratiopeptidase are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Anorexia, Gastrointestinal disturbances.

In patients with blood coagulation abnormalities, severe hepatic and renal disturbances or under treatment with anti-coagulants, should be given under careful observation. Serratiopeptidase may occasionally cause gastro-intestinal disturbances such as anorexia, gastric discomfort and nausea. Administration should be discontinued when hypersensitivity symptoms, such as eruption, appear.

Drug should not be given to Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

5 to 10 mg (7.5 (7.5)) 8 hourly PO — Before or after meal.

( ) — Not recommended in this age group

( ) — Not recommended in this age group

None well documented.

Tab Store Below 30°C. Protect from Sunlight and Moisture.